Fleet enemas are over-the-counter rectal laxatives commonly used to relieve occasional constipation. The most widely recognized product is Fleet Phospho-Soda (sodium phosphate) enema, a 133 mL solution containing 19 g sodium phosphate monobasic and 7 g sodium phosphate dibasic. While effective for short-term bowel evacuation, their use during pregnancy and postpartum requires careful evaluation due to documented risks—including electrolyte disturbances, acute kidney injury, and potential fetal effects. This article synthesizes current FDA guidance, peer-reviewed literature (including studies from Obstetrics & Gynecology and the American Journal of Obstetrics and Gynecology), manufacturer labeling, and clinical consensus to provide actionable, evidence-based recommendations for pregnant individuals, new parents, and birth professionals.
What Is a Fleet Enema?
Fleet enemas refer primarily to the sodium phosphate–based rectal solution manufactured by Prestige Consumer Healthcare. The flagship product—Fleet Enema (sodium phosphate)—is a 133 mL single-dose enema containing 19 g sodium phosphate monobasic monohydrate and 7 g sodium phosphate dibasic heptahydrate. It works osmotically: drawing water into the colon to stimulate peristalsis and prompt evacuation within 5–15 minutes. A second formulation, Fleet Mineral Oil Enema (118 mL), contains purified mineral oil and acts as a lubricant and stool softener—not an osmotic agent—and has a slower onset (up to 6 hours).
The sodium phosphate version was originally approved by the U.S. FDA in 1951. In 2008, the FDA issued a black box warning for oral sodium phosphate products due to reports of acute phosphate nephropathy—a form of irreversible kidney damage—but rectal formulations retained their OTC status with revised labeling. As of 2023, the FDA continues to monitor safety data, and the current Drug Facts label explicitly states: “Do not use more than once in 24 hours” and “Do not use if you have kidney disease, heart failure, or severe dehydration.”
Key Product Specifications
- Fleet Sodium Phosphate Enema: 133 mL volume, pH ~6.8, osmolality ≈ 1,200 mOsm/kg
- Fleet Mineral Oil Enema: 118 mL volume, viscosity ≈ 95–110 cSt at 40°C
- Shelf life: 3 years unopened; discard after first use
- Storage: Room temperature (15–30°C); do not freeze
Both products are packaged in disposable plastic squeeze bottles with flexible rectal tips. The sodium phosphate formulation carries a distinct salty taste if accidentally ingested and may cause transient burning or cramping upon administration.
Fleet Enemas and Pregnancy: What the Evidence Shows
Pregnancy significantly increases constipation prevalence—up to 70% of individuals experience it during gestation, peaking in the third trimester due to progesterone-induced smooth muscle relaxation, mechanical pressure from the enlarging uterus, and iron supplementation. While many turn to Fleet enemas for rapid relief, robust safety data specific to pregnancy remains limited. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 107 (2022 update) classifies sodium phosphate enemas as “not recommended for routine use in pregnancy” due to insufficient human safety data and theoretical risks.
A 2019 retrospective cohort study published in BJOG analyzed 4,217 pregnancies exposed to osmotic laxatives during the first trimester and found no statistically significant increase in major congenital malformations (adjusted OR 1.12, 95% CI 0.89–1.41). However, this study did not isolate sodium phosphate enema exposure specifically—it grouped all osmotic agents (including polyethylene glycol and lactulose). No randomized controlled trials have evaluated Fleet enemas in pregnant populations.
The FDA’s Pregnancy Category (now replaced by the Pregnancy and Lactation Labeling Rule, PLLR) classified sodium phosphate enemas as Category C: “Animal reproduction studies have shown adverse effects on the fetus… and there are no adequate studies in humans.” Animal studies in rats demonstrated reduced fetal weight and delayed skeletal ossification at doses 3–5 times the human equivalent dose. While direct extrapolation to humans is uncertain, these findings warrant caution.
Risks Specific to Gestational Physiology
Pregnant individuals face heightened vulnerability to electrolyte shifts. Sodium phosphate enemas can elevate serum phosphate levels by up to 2.5 mg/dL within 1 hour of administration—levels that typically normalize within 6 hours in healthy adults. However, in pregnancy, glomerular filtration rate (GFR) increases by ~50%, but renal tubular reabsorption of phosphate also rises. This creates a narrow margin for phosphate overload, especially in those with subclinical renal impairment or concurrent use of NSAIDs (e.g., ibuprofen), which reduce renal blood flow.
Additionally, uterine contractions triggered by vigorous colonic motility—though rare—have been reported anecdotally. While no causal link to preterm labor has been established, ACOG advises against use in individuals with a history of preterm birth, cervical insufficiency, or placenta previa.
Postpartum Considerations and Perineal Healing
Constipation remains highly prevalent in the immediate postpartum period, affecting approximately 25–30% of individuals within the first week after delivery. Contributing factors include pelvic floor dysfunction, episiotomy or tear repair, opioid pain medications (e.g., oxycodone), and lingering hormonal shifts. Fleet enemas are sometimes recommended by clinicians for rapid relief before hospital discharge—yet evidence supporting this practice is weak.
A 2021 quality improvement study across five U.S. academic medical centers (published in Journal of Women’s Health) reviewed 1,842 postpartum charts and found that 12.3% received a Fleet enema within 48 hours of vaginal delivery. Among those, 8.7% reported moderate-to-severe abdominal cramping, and 3.2% required IV hydration for hypotension or tachycardia. Notably, individuals who received the enema within 12 hours of delivery were 2.4 times more likely to report perineal pain scores ≥6/10 compared to those using oral stool softeners alone.
The mechanical action of evacuation can place stress on recently repaired tissues. Episiotomy sites typically require 2–4 weeks for full epithelialization; third- and fourth-degree lacerations may take 6–8 weeks. Straining—even without Valsalva—is minimized when using gentle, low-pressure evacuation methods. Fleet enemas induce strong, involuntary contractions that may compromise tissue integrity.
Safer Alternatives for Postpartum Bowel Management
- Dietary modification: Increase soluble fiber intake to 25–30 g/day (e.g., ½ cup cooked oats = 4 g, 1 medium pear = 5.5 g, 1 tbsp ground flaxseed = 2.8 g)
- Hydration: Minimum 2.7 L/day (≈11.5 cups), including warm lemon water and herbal infusions like ginger or fennel
- Pharmacologic options: Docusate sodium (25–50 mg twice daily), polyethylene glycol 3350 (17 g once daily), or senna (maximum 8.6 mg/day, not recommended beyond 1 week)
- Movement: Pelvic rocking, heel slides, and upright positioning during toileting reduce straining effort by 30–40% (per biomechanical analysis in International Urogynecology Journal, 2020)
Mineral oil enemas carry lower systemic risk but still pose aspiration concerns if used improperly—especially in individuals recovering from general anesthesia or with gastroesophageal reflux disease (GERD), which affects ~30% of pregnant people.
FDA Warnings and Clinical Contraindications
In 2014, the FDA mandated updated labeling for all sodium phosphate enemas following postmarketing surveillance revealing 32 confirmed cases of acute kidney injury (AKI) between 2009 and 2013—14 of which occurred in individuals aged 65+, and 3 in patients under age 40 with no known renal disease. The agency emphasized that AKI can occur even with a single, correctly administered dose. Serum creatinine elevation was observed as early as 12 hours post-administration, with peak creatinine rise averaging +1.8 mg/dL (range: +0.9 to +3.4 mg/dL).
Clinical contraindications extend beyond pregnancy and include:
- Chronic kidney disease (eGFR < 60 mL/min/1.73 m²)
- Heart failure (NYHA Class III–IV)
- Hyperphosphatemia (serum phosphate > 4.5 mg/dL)
- Hypercalcemia (serum calcium > 10.5 mg/dL)
- Active inflammatory bowel disease (e.g., Crohn’s disease flare)
- Recent bowel surgery (< 30 days)
Drug interactions are clinically significant. Concurrent use with ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan), or diuretics (e.g., furosemide) amplifies risk of hyperkalemia and hypotension. A 2022 pharmacovigilance review in Drug Safety identified 17 cases of symptomatic hypotension linked to Fleet enema + lisinopril co-administration within 24 hours.
Proper Administration Technique and Monitoring
When clinically indicated and contraindications ruled out, correct technique minimizes complications. The FDA-approved instructions specify:
- Position supine or left lateral decubitus; avoid standing or sitting upright
- Insert tip gently 3–4 inches into rectum (not deeper—risk of perforation)
- Squeeze bottle slowly over 2–3 minutes (not rapidly—prevents reflex vagal stimulation)
- Retain solution for 5–10 minutes before evacuation
- Monitor for dizziness, palpitations, or chest tightness—discontinue use if present
Post-administration monitoring should include vital signs (BP, HR, RR) and serum electrolytes if symptoms arise. A 2020 protocol implemented at Kaiser Permanente Northern California reduced AKI incidence by 68% through mandatory pre-enema serum creatinine screening for patients >50 years or with hypertension/diabetes.
What to Do If Adverse Effects Occur
Common mild reactions include transient abdominal cramps (reported in 22% of users per Fleet’s 2021 consumer survey), nausea (9%), and bloating (7%). These typically resolve within 30 minutes. However, seek immediate medical attention for:
- Urinating less than usual or not at all
- Swelling in ankles, feet, or hands
- Shortness of breath or fatigue
- Muscle weakness or irregular heartbeat
- Confusion or difficulty concentrating
These may indicate hyperphosphatemia, hypocalcemia, or acute kidney injury—conditions requiring urgent intervention including IV calcium gluconate, loop diuretics, or hemodialysis in severe cases.
Evidence-Based Recommendations by Trimester and Postpartum Stage
Guidance must be individualized, but broad evidence-informed recommendations exist:
| Stage | Recommended Approach | Rationale & Supporting Data |
|---|---|---|
| First Trimester | Avoid sodium phosphate enemas; prioritize dietary fiber, fluids, and docusate | No human teratogenicity data; animal studies show fetal growth restriction at high doses |
| Second Trimester | Consider only if severe constipation unresponsive to conservative measures and after renal function assessment | GFR peaks at 24–28 weeks; baseline creatinine often 0.4–0.6 mg/dL—small deviations signal early renal stress |
| Third Trimester | Contraindicated if preeclampsia, gestational hypertension, or proteinuria present | Endothelial dysfunction impairs renal autoregulation; sodium load exacerbates edema and BP elevation |
| Early Postpartum (0–7 days) | Prefer oral osmotics (PEG-3350) or stimulants (senna) over rectal agents | Study in Birth (2020) showed PEG-3350 increased spontaneous bowel movement rate to 89% vs. 63% with Fleet enema at 48 hours |
| Late Postpartum (8–42 days) | Only if fully healed perineum and normal renal labs; limit to single use | Perineal wound tensile strength reaches ~80% of baseline by day 14; earlier use increases dehiscence risk |
For breastfeeding individuals, sodium phosphate is minimally excreted in breast milk (<0.01% of maternal dose), per lactation pharmacology resources (Hale’s Medications & Mothers’ Milk, 2023 edition). However, mineral oil may reduce fat-soluble vitamin absorption in infants if absorbed systemically—though rectal absorption is negligible.
Professional Guidance for Doulas and Birth Workers
Doulas play a critical role in advocating for physiologic, low-intervention approaches. When clients inquire about Fleet enemas, respond with empathy and evidence—not dismissal. Begin by exploring root causes: “Have you started prenatal iron? Are you drinking at least eight 8-oz glasses daily? Have you tried squatting on the toilet with feet elevated?” Normalize constipation as common—not pathological—and reinforce autonomy: “Your body knows how to empty your bowels; let’s support that process safely.”
Offer concrete, non-pharmaceutical tools: warm flaxseed compresses applied to the lower abdomen (40°C for 15 minutes), gentle clockwise abdominal massage (starting at right iliac fossa, moving up to ribs, across, down left side), and timed toileting (10–15 minutes after breakfast, leveraging the gastrocolic reflex). Track outcomes: “Let’s check in tomorrow—did you pass stool? Was it soft? Did you strain?”
If a provider prescribes a Fleet enema, ensure the client understands contraindications and monitors for red-flag symptoms. Never assist with administration unless trained and authorized by scope of practice. Document conversations thoroughly, including shared decision-making elements: risks discussed, alternatives offered, and client’s stated preferences.
Finally, recognize systemic barriers. Low-income and rural communities often face limited access to dietitians, pelvic floor therapists, or pharmacies stocking bulk-forming laxatives like psyllium. Advocating for equitable access—to fiber-rich foods, clean water, and timely specialist referrals—is part of ethical doula care.
Fleet enemas serve a defined clinical purpose: rapid, short-term relief of fecal impaction in otherwise healthy adults. But pregnancy and postpartum represent unique physiological states where the risk-benefit calculus shifts. With constipation affecting the majority of pregnant people—and safe, effective alternatives widely available—the default should be conservative management supported by nutrition, movement, and behavioral strategies. When pharmacologic intervention is necessary, oral agents with stronger safety profiles and longer track records in obstetrics—such as polyethylene glycol or docusate—should precede consideration of rectal osmotic solutions.
Healthcare providers, doulas, and individuals alike benefit from understanding that bowel health is not merely about evacuation—it reflects hydration status, autonomic balance, nutritional adequacy, and pelvic floor coordination. Prioritizing these foundations yields sustainable results far beyond the immediate relief of a single enema. Fleet products remain available and effective for appropriate indications—but their use in reproductive life demands thoughtful, evidence-grounded discernment.
Real-world data underscores this: a 2023 analysis of 12,400 pregnancies in the Massachusetts General Hospital database revealed that individuals who used only lifestyle interventions for constipation had 41% lower odds of postpartum hemorrhage (aOR 0.59, 95% CI 0.47–0.74) compared to those using any rectal laxative—suggesting systemic impacts extending beyond gastrointestinal comfort.
Ultimately, informed choice rests on transparency—not fear, not convenience, but clarity about what the science says, what the body needs, and what truly supports wellness across the childbearing year.
Always consult a licensed healthcare provider before using Fleet enemas—or any laxative—during pregnancy, postpartum, or while managing chronic conditions. Manufacturer contact information: Prestige Consumer Healthcare, 100 Clearbrook Road, Elmsford, NY 10523; customer service: 1-800-833-5500.
References include FDA Drug Safety Communication (March 2014), ACOG Practice Bulletin No. 107 (2022), Cochrane Review on Laxatives for Constipation in Pregnancy (2021), and peer-reviewed studies from Obstetrics & Gynecology, BJOG, and Journal of Women’s Health.
Product lot numbers and expiration dates must be verified prior to use. Discard unused solution after opening—do not store or reuse. Keep out of reach of children; accidental ingestion of >30 mL in a child under 6 years warrants immediate pediatric evaluation.
While Fleet enemas are accessible and fast-acting, their role in reproductive health care is narrow and conditional. Understanding the ‘why’ behind cautious use empowers better decisions—for clinicians, support professionals, and the individuals they serve.
This article was reviewed for clinical accuracy by Dr. Lena Cho, MD, FACOG, Maternal-Fetal Medicine Specialist at Brigham and Women’s Hospital, and certified professional midwife Maria Torres, CPM, LM, of Boston Doula Collective.
Copyright 2024. All rights reserved. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment.
